

Resource Summary Report

Generated by [dkNET](#) on Jul 29, 2026

APC anti-human CD3

RRID:AB_1937212

Type: Antibody

Proper Citation

BioLegend Cat# 317318, RRID:AB_1937212

Antibody Information

URL: http://antibodyregistry.org/AB_1937212

Proper Citation: BioLegend Cat# 317318, RRID:AB_1937212

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: APC anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone OKT3

Antibody ID: AB_1937212

Vendor: BioLegend

Catalog Number: 317318

Alternative Catalog Numbers: 317317

Record Creation Time: 20250820T033130+0000

Record Last Update: 20250820T162909+0000

Ratings and Alerts

- Used for flow cytometry assay by the Human Islet Research Network community. Contact(s): [Jing Chen](#), [Mark Atkinson](#), [Todd Brusko](#), [Clayton Mathews](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for APC anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Zhou RW, et al. (2025) Safe immunosuppression-resistant pan-cancer immunotherapeutics by velcro-like density-dependent targeting of tumor-associated carbohydrate antigens. *Cell*.

Schiantarelli J, et al. (2025) Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma. *Cancer cell*, 43(2), 308.

Geilenkeuser J, et al. (2025) Engineered nucleocytosolic vehicles for loading of programmable editors. *Cell*, 188(10), 2637.

Wang S, et al. (2024) Loss of CDKN2A Enhances the Efficacy of Immunotherapy in EGFR Mutant Non-Small Cell Lung Cancer. *Cancer research*.

Abdelfattah NS, et al. (2024) T-Switch: A specificity-based engineering platform for developing safe and effective T cell therapeutics. *Immunity*, 57(12), 2945.

Liu Y, et al. (2024) IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects. *iScience*, 27(1), 108597.

Quiros-Fernandez I, et al. (2024) Dual T cell receptor/chimeric antigen receptor engineered NK-92 cells targeting the HPV16 E6 oncoprotein and the tumor-associated antigen L1CAM exhibit enhanced cytotoxicity and specificity against tumor cells. *Journal of medical virology*, 96(5), e29630.

Pan Q, et al. (2023) Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A*02:01 patients with advanced soft tissue sarcoma. *Cell reports. Medicine*, 4(8), 101133.

Wu L, et al. (2023) CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance. *Cell reports. Medicine*, 4(2), 100917.

Wu G, et al. (2023) Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia. *Frontiers in immunology*, 14, 1093750.

Long J, et al. (2023) A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment. *Cell reports. Medicine*, 4(11), 101286.

Wang C, et al. (2023) Dysregulated lung stroma drives emphysema exacerbation by potentiating resident lymphocytes to suppress an epithelial stem cell reservoir. *Immunity*, 56(3), 576.

Nelde A, et al. (2023) Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. *Blood cancer discovery*, 4(6), 468.

Zhang Z, et al. (2022) A covalent inhibitor of K-Ras(G12C) induces MHC class I presentation of haptenated peptide neoepitopes targetable by immunotherapy. *Cancer cell*, 40(9), 1060.

Alam A, et al. (2022) Fungal mycobiome drives IL-33 secretion and type 2 immunity in pancreatic cancer. *Cancer cell*, 40(2), 153.

Qian Y, et al. (2021) ZEB1 promotes pathogenic Th1 and Th17 cell differentiation in multiple sclerosis. *Cell reports*, 36(8), 109602.